GSK said Tuesday it would buy the cancer-focused biotech Nuvalent in a deal worth $10.6 billion, as the British firm ...

A targeted antibody‑drug conjugate shrinks tumors and slows progression in recurrent uterine cancer by ferrying potent ...

A new study co-led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center shows that the targeted cancer ...

A breakthrough targeted therapy, mirvetuximab soravtansine, is offering new hope to women with hard-to-treat ovarian cancer.

Johnson & Johnson will acquire Firefly Bio for $1 billion, adding cancer-targeting technology to expand its oncology pipeline ...

A new targeted ovarian cancer treatment is helping women with hard-to-treat disease live longer, feel better, and gain ...

Experiments in breast cancer models demonstrated a robust gene knockdown, resulting in an increased cancer cell death and a ...

Studies released in recent weeks are fueling optimism — and fresh questions — about GLP-1 drugs' potential role in cancer ...

Fewer than one-third of molecularly targeted cancer drugs recently approved by the US Food and Drug Administration (FDA) meet established European benchmarks for clinical benefits, according to a ...

A record 7 out of 10 cancer patients now survive for at least five years, up from less than half in the 1970s and 63% in the ...

A targeted treatment that triggers the death of cancer cells has shown promise for patients with advanced bowel cancer when ...

British pharmaceutical giant GSK plc (LON:GSK) is reportedly in advanced negotiations to acquire U.S.-based cancer drug ...